RE:Good Q3 Report --$23.5 million in cashReported sales of Intega products for Sept was $1.1 million or about $12 million per year.
Finished goods amounted to $3.3 million at Sept 30/ 16, so it looks like we are on a $13 million annual run rate which is quite good given that they are just beginning to expand the sales and marketing process.
Sept sales were 70% in Canada and 27% in US.
Acquiring Cipher's US dermatology assets with current sales of about $13 million with good upside growth potential would be a very strategic and accretive move..